Effect of liver-discharging and heat-clearing therapy for fire derived from stagnation of liver-QI type of generalized anxiety disorder and its influence on inflammatory cytokines

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17013058

Enrollment

Unknown

Registered

2017-10-20

Start date

2017-11-01

Completion date

Unknown

Last updated

2017-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalised Anxiety Disorder

Interventions

Group treated with Chinese herb:Take Shuganqingre granules and buspirone placebo

Control Group:Take buspirone and Shuganqingre placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Hospitalized or outpatient patients diagnosed with generalized anxiety disorder according to the International Classification of Diseases (ICD-10); 2. Meet with TCM criteria of Fire Derived from Stagnation of Liver-QI, including irritability, chest tightness, stalking rib pain accompanied by dry mouth, bitter taste ,constipation, or headache, red eyes, tinnitus, and so on 3. Aged between 18 and 65, male or female; 4. Screening and baseline scores of HAMA are between 14 and 29 ( including 14 and 39); 5. The patients or their legal guardian sign an informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with serious suicidal tendencies; 2. Patients with glaucoma,; with severe or unstable heart, liver, kidney, endocrine, blood and other internal diseases; accompanied by other disease with acute or chronic inflammatory cytokines level abnormalities (such as systemic lupus erythematosus, ulcerative colitis, etc.); 3. History of epilepsy, except for febrile convulsions in children; 4. drink alcohol and drug addicts within 1 year; 5. Anxiety secondary to other mental illness or somatic disease; 6. Women who are breastfeeding, pregnant or may be pregnant during the trial; 7. History of severe drug allergy; 8. Participated in other drug clinical trials within 30 days; 9. Monoamine oxidase ( MAO ) inhibitors was taken within 4 weeks before selection; 10. Buspirone was taken within 4 weeks before selection; 11. Unattended or unable to take medicine according to the doctor's orders; 12. Compared with screening, the reduction rate of the baseline Hama scale is =25%; 13. Allergic to buspirone; 14. When screening, the HAMD17 item scale score >7.

Design outcomes

Primary

Measure	Time frame
HAMA;	—

Secondary

Measure	Time frame
HAMD;TCM symptom scale;TESS;	—

Countries

China

Contacts

Public ContactJia Hongxiao

Beijing Anding Hospital, Capital Medical University

jhxlj@vip.163.com+86 010 58303065

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026